You can buy or sell RVNC and other stocks, options, ETFs, and crypto commission-free!
Revance Therapeutics, Inc. Common Stock, also called Revance Therapeutics, is a clinical stage biotechnology company. Read More It is engaged in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA.
52 Week High
52 Week Low
Yahoo FinanceMay 7
Is Revance Therapeutics Inc (RVNC) A Good Stock To Buy?
While the market driven by short-term sentiment influenced by uncertainty regarding the future of the interest rate environment in the US, declining oil prices and the trade war with China, many smart money investors kept their optimism regarding the current bull run in the fourth quarter, while still hedging many of their long positions.
Yahoo FinanceMay 1
A Spotlight On Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Fundamentals
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Building up an investment case requires looking at a stock holistically. Today I've chosen to put the spotlight on Revance Therapeutics, Inc. (NASDAQ:RVNC) due to its excellent fundamentals in more than one area. RVNC is a company with strong financial health as well as an optimistic future outlook. Below, I've touched on some key aspects you should know on a high level. For those int...
Yahoo FinanceMay 1
Will Revance Therapeutics (RVNC) Report Negative Earnings Next Week? What You Should Know
Wall Street expects a year-over-year increase in earnings on higher revenues when Revance Therapeutics (RVNC) reports results for the quarter ended March 2019. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
Expected Aug 1, After Hours